Department of Critical Medicine, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 325000 Wenzhou, Zhejiang, China.
Arch Esp Urol. 2024 Jan;77(1):67-71. doi: 10.56434/j.arch.esp.urol.20247701.9.
Acute kidney injury (AKI) is common in patients with sepsis and may result in death. Systemic immune inflammation index (SII) is associated with kidney injury, but its predictive value for AKI in patients with sepsis remains unclear.
This study aimed to explore the predictive value of SII in sepsis patients with AKI.
From January 2020 to December 2022, 221 patients with sepsis treated in our hospital were retrospectively collected. The patients were divided into AKI group (n = 61) and control group (n = 160). Clinical characteristics and SII level were compared between the two groups, and the predictive value of SII for the occurrence of AKI was analysed.
The SII level (724.72 ± 235.50 vs. 522.38 ± 205.62, < 0.001), the serum procalcitonin level (8.13 ± 15.52 vs. 4.52 ± 10.34 µg/L, < 0.001), and the acute physiology and chronic health evaluation II score (14.26 ± 2.90 vs. 11.62 ± 2.26, < 0.001) significantly increased in the AKI group compared with the control group, whereas the albumin level significantly decreased (30.60 ± 5.41 vs. 32.49 ± 5.31 g/L, = 0.019). The receiver operating characteristic curve showed that SII was valuable in predicting AKI in patients with sepsis, with an area under the curve of 0.733 (95% confidence interval: 0.657-0.810, < 0.001). The continuous renal replacement therapy intervention rate (88.52% vs. 0.00%, < 0.001), the intervention rate of vasoactive drugs (34.43% vs. 3.75%, < 0.001), and the hospital mortality rate (16.39% vs. 2.50%, < 0.001) significantly increased in the AKI group compared with the control group.
AKI was associated with poor prognosis in patients with sepsis. SII, procalcitonin and acute physiology and chronic health evaluation II (APACHE II) score were valuable in predicting the occurrence of AKI. SII may serve as a new marker in patients with sepsis.
急性肾损伤(AKI)在脓毒症患者中很常见,可能导致死亡。全身免疫炎症指数(SII)与肾损伤有关,但它对脓毒症患者 AKI 的预测价值尚不清楚。
本研究旨在探讨 SII 在脓毒症合并 AKI 患者中的预测价值。
回顾性收集 2020 年 1 月至 2022 年 12 月我院收治的 221 例脓毒症患者的临床资料。患者分为 AKI 组(n=61)和对照组(n=160)。比较两组患者的临床特征和 SII 水平,分析 SII 对 AKI 发生的预测价值。
AKI 组 SII 水平(724.72±235.50比 522.38±205.62, < 0.001)、血清降钙素原水平(8.13±15.52比 4.52±10.34μg/L, < 0.001)、急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分(14.26±2.90比 11.62±2.26, < 0.001)明显高于对照组,白蛋白水平明显降低(30.60±5.41比 32.49±5.31g/L, = 0.019)。受试者工作特征曲线显示,SII 对脓毒症患者 AKI 具有预测价值,曲线下面积为 0.733(95%置信区间:0.657-0.810, < 0.001)。AKI 组连续性肾脏替代治疗干预率(88.52%比 0.00%, < 0.001)、血管活性药物干预率(34.43%比 3.75%, < 0.001)和医院病死率(16.39%比 2.50%, < 0.001)明显高于对照组。
AKI 与脓毒症患者的不良预后相关。SII、降钙素原和急性生理学与慢性健康状况评分系统Ⅱ(APACHEⅡ)评分对 AKI 的发生具有预测价值。SII 可能成为脓毒症患者的一个新标志物。